・Plus has appointed Eric J. Daniels as its chief development officer, effective April 20. ・The company also received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma ...
Shares of Plus Therapeutics, Inc. PSTV were up a staggering 170.1% on March 20 after the company announced that the FDA has conditionally accepted — Reyobiq — as the new proprietary name for PSTV's ...
Shares of Plus Therapeutics, Inc. PSTV were up a whopping 311.4% on March 6 after the company announced that the FDA has granted an Orphan Drug Designation ("ODD") to its lead radiotherapeutic ...
Detailed price information for Plus Therapeutics Inc (PSTV-Q) from The Globe and Mail including charting and trades.
PLUS THERAPEUTICS ($PSTV) posted quarterly earnings results on Thursday, March 27th. The company reported earnings of -$0.67 per share, missing estimates of -$0.51 by ...
Plus Therapeutics (PSTV) shares plunged 35% premarket after the healthcare company launched an offering of 39.47M units to raise around $15M in proceeds. Each unit consists of one share of common ...
Plus Therapeutics Inc (NASDAQ:PSTV) shares are trading higher by 244% to $1.75 during Thursday’s session after the company announced that the FDA accepted the name REYOBIQ for the company’s lead asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results